The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs In inflammatory bowel disease patients

European Journal of Gastroenterology and Hepatology

Volumn 29, Issue 2, 2017, Pages 169-173

  Taks, Margot ^a   Pijls, Phillipe A R R ^a   Derijks, Luc J J ^b   Broeke, Robert Ten ^a   Grouls, Rene J ^a   Curvers, Joyce ^a   Gilissen, Lennard P L ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Therapeutic drug monitoring; Treatment algorithm; Ulcerative colitis

Indexed keywords

ADALIMUMAB; CALGRANULIN; GOLIMUMAB; INFLIXIMAB; ANTIBODY; GASTROINTESTINAL AGENT;

ADULT; ALGORITHM; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; COST CONTROL; DRUG COST; DRUG FECES LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; BLOOD; CLINICAL TRIAL; ECONOMICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTIBODIES; COHORT STUDIES; DRUG COSTS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84991500779     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000763     Document Type: Article

References (17)

1. Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2015;27:242-248.
2. Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res 2014;163:533-556.
3. Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. Dan Med J 2013;60:B4616.
4. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-1254.
5. Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol 2015;15:178.
6. Paul S, Del TE, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013;19:2568-2576.
7. Buhl SS, Steenholdt C, Brynskov J. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebocontrolled, multicentre trial. BMJ Open 2014;4:e005887.
8. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-927.
9. Vande Casteele N, Ferrante M, van Assche G, Ballet V, Compernolle G, van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-1329.
10. Van den Broek M. Infliximab [in Dutch]. TDM-Monografie [online mono graphs] 2014. http://tdm-monografie.org/monografie/infliximab. [Accessed 1 February 2014].
11. Burri E, Beglinger C. Faecal calprotectin - a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012;142:w13557.
12. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999;13:65-73.
13. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-1048.
14. Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31:336-344.
15. Pittet V, Froehlich F, Maillard M, Mottet C, Gonvers JJ, Felley C. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J Crohns Colitis 2013;4:1-7.
16. Hanauer SB. Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease. Curr Gastroenterol Rep 2007;9:487-488.
17. Vande Casteele N, Khanna R, Levesque B, Stitt L, Zou G, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015;10:1539-1545.